NCI must make a bigger investment in new cancer therapies and expand the clinical trials system that tests them, the institute’s Acting Director Douglas Lowy said in his remarks at the American Society of Clinical Oncology annual meeting June 4.
What should a cancer center look like in an era of AI, genomics, complex patient populations, rising costs, and declining public trust in science?
